Economic Evaluation of Microneedles for Vaccinations

Nguyen, Hiep X.; Vu, Michelle; Nguyen, Loc H.

doi:10.4172/2329-6887.1000e174

Cited by 1 publication

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only four research articles on MNs economic evaluation have been accessed to date, and all of them have focused on vaccination application. [194][195][196][197] The following evaluation aspects can provide a cost-benefit overview to the developers and help in decisions making which rational option to go forward and which to forgo. For instance, the cost analysis involving direct costs (manufacturing, inventory, raw materials, manufacturing expenses), indirect costs (electricity, management overhead costs, rent, utilities), intangible costs (impact on customers, employees, or delivery times), opportunity costs (investments equipment), and potential risk-related costs such as regulatory, competition, and environmental is extremely beneficial.…”

Section: Economic Perspectivementioning

confidence: 99%

See 1 more Smart Citation

Concept Design of Transdermal Microneedles for Diagnosis and Drug Delivery: A Review

2021

View full text Add to dashboard Cite

Microneedles (MNs) are one of intriguing approach for efficient transdermal drug delivery that penetrates the protective skin barrier in a painless and less invasive way. In recent years, multidisciplinary studies have been conducted to improve their properties to meet stringent requirements and obtain market release approval. This review aims to summarize the latest concept design with unique properties in the advancement of transdermal MNs for diagnosis and therapeutic application. Numerous significant innovation strategies in improving MNs in aspects of adhesion ability, dosing capacity, drug‐controlled release, diffusion control ability, site‐targeted and on‐demand drug delivery, and biomarker or drug release monitoring are presented. Given that the majority of technologies used in such design are exclusively laboratory‐based, striving toward commercialization is a critical aspect of the revolution. Key challenges and future perspectives in industrial and economic aspects are identified with the intention of translating the reviewed technologies into marketable products.

show abstract

Section: Economic Perspectivementioning

confidence: 99%

“…During the influenza season, MNs save $950 million for third‐party payers and as much as $2.6 billion for society. [ 197 ] In this section, economic challenges in unit cost healthcare devices and life cycle of view are discussed.…”

Section: Challenge and Future Perspectivementioning

confidence: 99%